JP4291417B2 - 放射性同位体によって標識されたペプチドのための放射線保護剤 - Google Patents

放射性同位体によって標識されたペプチドのための放射線保護剤 Download PDF

Info

Publication number
JP4291417B2
JP4291417B2 JP50281899A JP50281899A JP4291417B2 JP 4291417 B2 JP4291417 B2 JP 4291417B2 JP 50281899 A JP50281899 A JP 50281899A JP 50281899 A JP50281899 A JP 50281899A JP 4291417 B2 JP4291417 B2 JP 4291417B2
Authority
JP
Japan
Prior art keywords
composition
radiolabeled
povidone
peptide
mci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50281899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002516612A (ja
JP2002516612A5 (https=
Inventor
ショチャット，ダン
エス．，ケー． チャン，アルバート
ジェイ． バックレー，マイケル
Original Assignee
スミスクライン ビーチャム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミスクライン ビーチャム コーポレーション filed Critical スミスクライン ビーチャム コーポレーション
Publication of JP2002516612A publication Critical patent/JP2002516612A/ja
Publication of JP2002516612A5 publication Critical patent/JP2002516612A5/ja
Application granted granted Critical
Publication of JP4291417B2 publication Critical patent/JP4291417B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP50281899A 1997-06-03 1998-06-03 放射性同位体によって標識されたペプチドのための放射線保護剤 Expired - Fee Related JP4291417B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4838797P 1997-06-03 1997-06-03
US60/048,387 1997-06-03
US08/918,525 US5961955A (en) 1997-06-03 1997-08-21 Radioprotectant for peptides labeled with radioisotope
US08/918,525 1997-08-21
PCT/US1998/011428 WO1998055154A1 (en) 1997-06-03 1998-06-03 Radioprotectant for peptides labeled with radioisotope

Publications (3)

Publication Number Publication Date
JP2002516612A JP2002516612A (ja) 2002-06-04
JP2002516612A5 JP2002516612A5 (https=) 2005-12-22
JP4291417B2 true JP4291417B2 (ja) 2009-07-08

Family

ID=26726075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50281899A Expired - Fee Related JP4291417B2 (ja) 1997-06-03 1998-06-03 放射性同位体によって標識されたペプチドのための放射線保護剤

Country Status (14)

Country Link
US (2) US5961955A (https=)
EP (1) EP1003560B1 (https=)
JP (1) JP4291417B2 (https=)
AT (1) ATE249845T1 (https=)
AU (1) AU743823B2 (https=)
CA (1) CA2290987A1 (https=)
DE (1) DE69818272T2 (https=)
DK (1) DK1003560T3 (https=)
ES (1) ES2212304T3 (https=)
IL (1) IL133271A (https=)
NO (1) NO315693B1 (https=)
NZ (1) NZ502029A (https=)
PT (1) PT1003560E (https=)
WO (1) WO1998055154A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
ATE259247T1 (de) 1998-06-02 2004-02-15 Dow Global Technologies Inc Radiojodierte phenole für brachytherapie
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
KR100330733B1 (ko) * 1999-11-30 2002-04-03 노광 폴리에틸렌글리콜포스페이트, 그의 합성방법 및 그를방사능보호제로 사용하는 방법
AU2002211232B2 (en) * 2000-09-15 2006-10-19 Sloan Kettering Institute For Cancer Research Targeted alpha particle therapy using actinium-225 conjugates
JP2004529884A (ja) * 2001-02-26 2004-09-30 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー 金属放射性医薬のためのアスコルビン酸類似体
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7238338B1 (en) 2001-06-22 2007-07-03 Triumf System and method for the large scale labeling of compounds with radiohalogens
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
AU2003248679A1 (en) * 2002-06-14 2003-12-31 Actinium Pharmaceuticals Ltd. Treating disease using radium-225
US7018614B2 (en) * 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
KR20110140143A (ko) 2002-11-26 2011-12-30 애보트 바이오테라퓨틱스 코포레이션 혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및 인간화 항체
EP1444990A1 (en) * 2003-02-07 2004-08-11 Amersham plc Improved Radiometal Complex Compositions
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
ES2456671T3 (es) 2005-02-25 2014-04-23 Tetralogic Pharmaceuticals Corporation Inhibidores diméricos de IAP
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007021825A2 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
KR20090041391A (ko) * 2006-07-24 2009-04-28 테트랄로직 파마슈티칼스 이량체성 ｉａｐ 길항제
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CL2007002166A1 (es) * 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5297815B2 (ja) 2007-01-26 2013-09-25 株式会社ポーラファルマ 医薬組成物
CN101678082B (zh) 2007-03-26 2013-06-19 再生医药有限公司 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
AU2009220244B2 (en) 2008-02-29 2014-10-09 Lantheus Medical Imaging, Inc. Contrast agents for applications including perfusion imaging
KR20110097772A (ko) * 2008-11-17 2011-08-31 제넨테크, 인크. 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제
KR101602992B1 (ko) 2009-04-15 2016-03-11 랜티우스 메디컬 이메징, 인크. 아스코르브산을 사용한 방사성 약제 조성물의 안정화
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
CN102858752B (zh) 2010-02-08 2018-10-16 兰休斯医疗成像公司 用于合成显像剂和其中间体的方法和装置
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
JP2016510342A (ja) * 2013-02-15 2016-04-07 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 腫瘍画像化のためのキット
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US10610807B2 (en) * 2014-01-17 2020-04-07 Repligen Corporation Sterilizing chromatography columns
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
HUE071169T2 (hu) 2016-03-07 2025-08-28 Actinium Pharmaceuticals Inc Stabilizált, radioaktívan jelölt anti-CD45 immunglobulin-készítmények
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
US12599669B2 (en) 2019-04-23 2026-04-14 Amgen Inc. Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations
WO2022265912A1 (en) 2021-06-16 2022-12-22 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope
CN121532218A (zh) 2023-06-16 2026-02-13 普罗热尼奇制药公司 前列腺特异性膜抗原（psma）放射性标记抑制剂[18f]dcfpyl的改进的合成

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE933885C (de) * 1952-06-22 1955-10-06 Helmut Richard Dr Kanitz Verfahren zur Herstellung kolloidaler Loesungen radioaktiver Metalle wie radioaktiver Goldisotope
US4421735A (en) * 1980-04-17 1983-12-20 The Massachusetts General Hospital Radiolabeled diagnostic compositions and method for making the same
US4427631A (en) * 1982-05-27 1984-01-24 Euroceltique, S.A. Povidone irradiation
US4411881A (en) * 1982-07-12 1983-10-25 New England Nuclear Corporation Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines
EP0111414A3 (en) * 1982-12-08 1985-05-02 Mallinckrodt, Inc. (a Delaware corporation) Radiographic imaging agents
US4676979A (en) * 1984-12-31 1987-06-30 Eastern Virginia Medical Authority/Med. Ctr. Hosp. Method of protecting animals against ionizing radiation
US5393512A (en) * 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
US5061641A (en) * 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
RO103925B1 (ro) * 1989-02-27 1992-04-26 Institutul De Chimie Macromoleculara "P.Poni" Derivat de polivinilpirolidona si procedeu de preparare
WO1991004057A1 (en) * 1989-09-22 1991-04-04 Neorx Corporation Stable therapeutic radionuclide compositions and methods for preparation thereof
US5011676A (en) * 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
WO1993002652A2 (en) * 1991-08-01 1993-02-18 Hybritech Incorporated Modified haptens useful as imaging and therapeutic agents
DK0600992T3 (da) * 1991-08-29 2000-10-09 Mallinckrodt Medical Inc Anvendelse af gentissyre eller gentisylalkohol til stabilisering af radiomærkede peptider og proteiner
ATE132842T1 (de) * 1992-04-30 1996-01-15 Amersham Int Plc Formulierungen von radiomarkierten verbindungen
CA2120023A1 (en) * 1992-07-28 1994-02-03 Noriaki Uenishi Immunoconjugate
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope

Also Published As

Publication number Publication date
US6338835B1 (en) 2002-01-15
EP1003560A1 (en) 2000-05-31
IL133271A (en) 2004-06-01
NZ502029A (en) 2001-12-21
NO995906L (no) 1999-12-03
EP1003560B1 (en) 2003-09-17
WO1998055154A1 (en) 1998-12-10
AU8057098A (en) 1998-12-21
DK1003560T3 (da) 2003-12-01
NO315693B1 (no) 2003-10-13
JP2002516612A (ja) 2002-06-04
CA2290987A1 (en) 1998-12-10
AU743823B2 (en) 2002-02-07
IL133271A0 (en) 2001-04-30
US5961955A (en) 1999-10-05
ES2212304T3 (es) 2004-07-16
NO995906D0 (no) 1999-12-02
ATE249845T1 (de) 2003-10-15
DE69818272T2 (de) 2004-07-01
DE69818272D1 (de) 2003-10-23
WO1998055154A9 (en) 1999-04-08
PT1003560E (pt) 2004-02-27

Similar Documents

Publication Publication Date Title
JP4291417B2 (ja) 放射性同位体によって標識されたペプチドのための放射線保護剤
US6024938A (en) Lyophilized imaging agent formulation comprising a chemotactic peptide
TWI283178B (en) Method and kit for efficient radiolabeling of proteins with therapeutic radioisotopes
US5605671A (en) Radiolabeled neutrophil activating peptides for imaging
EP0670736B1 (en) Labelled interleukin-8 and medical uses thereof
Rennen et al. Specific and rapid scintigraphic detection of infection with 99mTc-labeled interleukin-8
RU2741794C2 (ru) Радиофармацевтические растворы с предпочтительными свойствами
CA2279349C (en) Ascorbate-stabilized radiopharmaceutical method and composition
van der Laken et al. Imaging of infection in rabbits with radioiodinated interleukin-1 (α and β), its receptor antagonist and a chemotactic peptide: a comparative study
DeNardo et al. Are radiometal-labeled antibodies better than iodine-131–labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67–, iodine-131–, and yttrium-90–labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma
US20100047167A1 (en) Combination therapy in the treatment of cancer
CN100586484C (zh) 用于放射治疗软组织疾病的钍-227
Adams et al. Effect of mass of 111In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice
Signore et al. Biological imaging for the diagnosis of inflammatory conditions
Signore et al. [68Ga] Ga-interleukin-2 for imaging activated T-lymphocytes: biochemical characterization and phase I study in normal subjects
Macfarlane et al. Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′
Meckel et al. Reduced renal uptake of various radiopharmaceuticals with sodium paraaminohippurate coadministration in a rat model
Singh et al. A simplified kit for instant preparation of technerium-99m human immunoglobulin-G for imaging inflammatory foci
Kurizaki et al. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a
Reynolds et al. Radiohalogenation of monoclonal antibodies: Experiences with radioiodination of monoclonal antibodies for radioimmunotherapy
Ballantyne et al. Experience with a commercial preparation of 125I-labelled human albumin for study of albumin metabolism
Tsopelas et al. Evaluation of 99mTc‐immunoglobulins for imaging infection in the rat
Broer et al. 89Zr-brentuximab development for whole-body PET imaging of patients with CD30 positive lymphoma, eligible for brentuximab-vedotin therapy
Chopra 99m Tc-Labeled rituximab, a chimeric murine/human anti-CD20 monoclonal antibody [99m Tc] Rituximab

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050527

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090310

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090403

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120410

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130410

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140410

Year of fee payment: 5

LAPS Cancellation because of no payment of annual fees